|
|
|
 |
| Location: Home -
Products - Reference Compounds&Impurities - Anti-Cancer(Oncology) Agents
|
Alisertib(MLN-8237)
| Catalogue No. : |
C15972 |
| Product Name: |
Alisertib(MLN-8237) |
| Synonym: |
MLN8237;MLN 8237;MLN-8237 |
| Chemical Name: |
4-[[9-Chloro-7-(2-fluoro-6-methoxyphenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-yl]amino]-2-methoxybenzoic acid |
| CAS No. : |
1028486-01-2 |
| Structure : |
|
| Molecular Formula: |
C27H20ClFN4O4 |
| Molecular Weight: |
518.92 |
| Purity: |
>98% |
| Usage: |
MLN8237 is a second-generation, orally bioavailable, highly selective small molecule inhibitor of the serine/threonine protein kinase Aurora A kinase with potential antineoplastic activity. Aurora kinase inhibitor MLN8237 binds to and inhibits Aurora A kinase, which may result in disruption of the assembly of the mitotic spindle apparatus, disruption of chromosome segregation, and inhibition of cell proliferation. Aurora A kinase localizes to the spindle poles and to spindle microtubules during mitosis, and is thought to regulate spindle assembly. Aberrant expression of Aurora kinases occurs in a wide variety of cancers, including colon and breast cancers. |
|
| Products protected by valid patents are not offered for sale in countries, where the sale of such products constitutes a patent infringement. As it is impossible for us to be informed about the patent situation in all countries, the liability for patent infringement is exclusively to be understood as buyer's risk. |
|
|
